Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.

Name: Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
License: Public Domain

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

ClinicalTrials.gov · Datasets · License: Public Domain

non small cell lung cancer (nsclc)

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 683087
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.